GlucoTrack, Inc. (NASDAQ:GCTK) Sees Significant Drop in Short Interest

GlucoTrack, Inc. (NASDAQ:GCTK) saw a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 28,292 shares, a decrease of 24.6% from the February 12th total of 37,508 shares. Currently, 2.9% of the shares of the stock are sold short. Based on an average trading volume of 37,296 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 37,296 shares, the short-interest ratio is currently 0.8 days. Currently, 2.9% of the shares of the stock are sold short.

GlucoTrack Trading Down 4.7%

NASDAQ:GCTK traded down $0.06 during trading hours on Friday, hitting $1.21. The company had a trading volume of 77,806 shares, compared to its average volume of 40,606. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average of $2.38 and a 200 day moving average of $4.64. The company has a market cap of $1.22 million, a P/E ratio of -0.03 and a beta of 0.33. GlucoTrack has a 1 year low of $1.11 and a 1 year high of $30.51.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its holdings in shares of GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after purchasing an additional 4,085 shares during the period. Boothbay Fund Management LLC acquired a new stake in GlucoTrack during the fourth quarter worth about $52,000. Finally, Ikarian Capital LLC purchased a new position in GlucoTrack during the fourth quarter worth about $177,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.